Want to see VRCA full AI Analyst Report?
Verrica Pharmaceuticals (VRCA) Ratios
Verrica Pharmaceuticals Ratios
VRCA's free cash flow for Q2 2026 was $-9.28M. For the 2026 fiscal year, VRCA's free cash flow was increased by $0.00 and operating cash flow was $-9.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.59 | 1.76 | 4.55 | 11.31 | 1.61 |
| Quick Ratio | 2.45 | 1.68 | 4.49 | 11.31 | 1.61 |
| Cash Ratio | 1.83 | 1.60 | 4.09 | 9.91 | 0.34 |
| Solvency Ratio | -0.76 | -1.18 | -1.07 | -5.07 | -0.73 |
| Operating Cash Flow Ratio | -1.07 | -2.10 | -2.27 | -5.39 | -0.60 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -4.71 | 0.00 | 0.00 | -0.66 |
| Net Current Asset Value | $ 20.15M | $ -12.81M | $ 15.70M | $ 34.43M | $ 26.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.85 | 0.56 | 0.03 | 0.54 |
| Debt-to-Equity Ratio | 0.07 | -4.66 | 2.30 | 0.04 | 1.33 |
| Debt-to-Capital Ratio | 0.06 | 1.27 | 0.70 | 0.04 | 0.57 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 1.47 | 0.68 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.90 | -5.49 | 4.13 | 1.12 | 2.46 |
| Debt Service Coverage Ratio | -1.21 | -2.95 | -15.70 | -9.94 | -0.66 |
| Interest Coverage Ratio | -1.54 | -7.00 | -16.60 | -9.80 | -7.20 |
| Debt to Market Cap | 0.00 | 1.21 | 0.13 | 0.00 | 0.17 |
| Interest Debt Per Share | 0.88 | 10.68 | 10.91 | 1.08 | 17.64 |
| Net Debt to EBITDA | 3.05 | 0.01 | 0.39 | 1.52 | -0.91 |
| Profitability Margins | |||||
| Gross Profit Margin | 90.33% | 63.79% | 85.44% | 91.97% | 96.07% |
| EBIT Margin | -28.51% | -887.75% | -1230.15% | -247.07% | -256.54% |
| EBITDA Margin | -26.32% | -870.98% | -1213.84% | -239.12% | -252.61% |
| Operating Profit Margin | -33.56% | -871.25% | -1283.35% | -235.78% | -257.57% |
| Pretax Profit Margin | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% |
| Net Profit Margin | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% |
| Continuous Operations Profit Margin | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 149.81% | 116.17% | 101.88% | 114.98% | 113.50% |
| Return on Assets (ROA) | -37.95% | -141.46% | -82.10% | -54.76% | -43.78% |
| Return on Equity (ROE) | -72.29% | 776.66% | -338.99% | -61.17% | -107.59% |
| Return on Capital Employed (ROCE) | -38.90% | -262.40% | -101.84% | -51.61% | -90.72% |
| Return on Invested Capital (ROIC) | -37.97% | -170.21% | -100.74% | -51.24% | -40.66% |
| Return on Tangible Assets | -37.95% | -141.46% | -82.10% | -54.76% | -43.78% |
| Earnings Yield | -20.21% | -211.16% | -20.18% | -26.06% | -14.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.59 | 98.26 | 1.16 | 18.55 | 0.00 |
| Payables Turnover | 1.66 | 1.45 | 0.30 | 1.43 | 0.56 |
| Inventory Turnover | 1.54 | 1.11 | 0.73 | 0.00 | 0.00 |
| Fixed Asset Turnover | 19.11 | 2.93 | 1.42 | 1.69 | 2.18 |
| Asset Turnover | 0.75 | 0.14 | 0.06 | 0.20 | 0.15 |
| Working Capital Turnover Ratio | 1.47 | 0.18 | 0.11 | 0.28 | 0.43 |
| Cash Conversion Cycle | 72.77 | 79.25 | -390.97 | -235.57 | -653.44 |
| Days of Sales Outstanding | 55.37 | 3.71 | 314.57 | 19.68 | 0.00 |
| Days of Inventory Outstanding | 237.18 | 328.10 | 500.04 | 0.00 | 0.00 |
| Days of Payables Outstanding | 219.78 | 252.57 | 1205.58 | 255.25 | 653.44 |
| Operating Cycle | 292.55 | 331.82 | 814.61 | 19.68 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.65 | -11.76 | -8.51 | -5.46 | -10.20 |
| Free Cash Flow Per Share | -1.65 | -11.77 | -8.59 | -5.55 | -10.53 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -2256.56 | -106.57 | -61.75 | -31.24 |
| Capital Expenditure Coverage Ratio | 0.00 | -2256.56 | -106.57 | -61.75 | -31.24 |
| Operating Cash Flow Coverage Ratio | -10.81 | -1.33 | -0.85 | -12.22 | -0.64 |
| Operating Cash Flow to Sales Ratio | -0.50 | -8.05 | -7.53 | -2.06 | -2.30 |
| Free Cash Flow Yield | -19.91% | -168.08% | -11.73% | -20.17% | -11.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.95 | -0.47 | -4.95 | -3.84 | -7.06 |
| Price-to-Sales (P/S) Ratio | 2.49 | 4.79 | 64.77 | 10.40 | 20.64 |
| Price-to-Book (P/B) Ratio | 3.58 | -3.68 | 16.79 | 2.35 | 7.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.02 | -0.59 | -8.52 | -4.96 | -8.70 |
| Price-to-Operating Cash Flow Ratio | -5.02 | -0.60 | -8.60 | -5.04 | -8.98 |
| Price-to-Earnings Growth (PEG) Ratio | 0.06 | 0.00 | -0.05 | 0.09 | 0.29 |
| Enterprise Value Multiple | -6.41 | -0.54 | -4.95 | -2.83 | -9.08 |
| Enterprise Value | 60.01M | 35.88M | 307.87M | 61.20M | 275.38M |
| EV to EBITDA | -6.41 | -0.54 | -4.95 | -2.83 | -9.08 |
| EV to Sales | 1.69 | 4.74 | 60.08 | 6.78 | 22.95 |
| EV to Free Cash Flow | -3.40 | -0.59 | -7.91 | -3.23 | -9.67 |
| EV to Operating Cash Flow | -3.40 | -0.59 | -7.98 | -3.28 | -9.98 |
| Tangible Book Value Per Share | 2.32 | -1.90 | 4.36 | 11.72 | 12.06 |
| Shareholders’ Equity Per Share | 2.32 | -1.90 | 4.36 | 11.72 | 12.06 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 3.34 | 1.46 | 1.13 | 2.64 | 4.44 |
| Net Income Per Share | -1.68 | -14.78 | -14.78 | -7.17 | -12.97 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.76 | 1.14 | 1.06 | 1.10 | 1.14 |
| Research & Development to Revenue | 0.25 | 1.56 | 3.96 | 1.35 | 1.33 |
| SG&A to Revenue | 0.99 | 7.77 | 9.23 | 1.93 | 2.25 |
| Stock-Based Compensation to Revenue | 0.09 | 0.95 | 2.81 | 0.55 | 0.50 |
| Income Quality | 0.99 | 0.80 | 0.58 | 0.76 | 0.79 |
Currency in USD
